Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

UCB to Acquire Candid Therapeutics for $2.2B, Gaining Best-in-Class BCMA T-Cell Engager Cizutamig for Autoimmune Diseases

Fineline Cube May 6, 2026
Company Deals

SiranBio Inks $1.005B Licensing Deal with GSK for First-in-Class siRNA Therapy SA030 Targeting ALK7 in Cardiometabolic Disease

Fineline Cube May 6, 2026
Company Deals

Teva to Acquire Emalex Biosciences for $700M, Adding Registration-Ready Tourette Syndrome Drug Ecopipam

Fineline Cube Apr 30, 2026
Company Deals

Eccogene Files Hong Kong IPO Prospectus with THR-β Agonist ECC4703 Leading Metabolic Disease Pipeline

Fineline Cube Apr 30, 2026
Company Deals

Hengrui Pharmaceuticals Replaces Hansoh as Exclusive Licensee for KiOmed’s Osteoarthritis Drug in Greater China

Fineline Cube Apr 30, 2026
Policy / Regulatory

China’s NHC Establishes Regulatory Framework for Biomedical New Technologies with Interim Guiding Principles Effective May 1, 2026

Fineline Cube May 6, 2026
Company Drug

Senhwa Biosciences Launches Global Phase I/II Trial of First-in-Class Pidnarulex Combined with BeOne’s Tislelizumab in Solid Tumors Including Pancreatic Cancer

Fineline Cube May 6, 2026
Company Drug

AstraZeneca’s Truqap Receives Positive ODAC Recommendation for PTEN-Deficient mHSPC Based on CAPItello-281 Trial Data

Fineline Cube May 6, 2026
Company Drug

Chia Tai Tianqing’s Benmelstobart and Anlotinib Combo Meets Primary Endpoint in Phase III Study

Fineline Cube Dec 27, 2024

China-based Chia Tai Tianqing Pharmaceutical, a subsidiary of Sino Biopharmaceutical Ltd (HKG: 1177), has announced...

Company Drug

China Isotope & Radiation Corporation’s [18F] Piramide Receives NMPA Clinical Trial Approval

Fineline Cube Dec 27, 2024

On December 24, 2024, China Isotope & Radiation Corporation (HKG: 1763) announced that its subsidiary,...

Company Drug

Hybio Pharmaceutical Receives US FDA Approval for Biosimilar Victoza (Liraglutide)

Fineline Cube Dec 26, 2024

China-based Hybio Pharmaceutical Co., Ltd (SHE: 300199) has announced receiving official approval from the US...

Company Drug

Shanxi C&Y Pharmaceutical Initiates Clinical Study for Generic Ferric Maltol with NMPA Approval

Fineline Cube Dec 26, 2024

China’s Shanxi C&Y Pharmaceutical Group Co., Ltd (SHE: 300254) has announced the initiation of a...

Company Drug

Boji Medical Technology Receives NMPA Approval for TBA Clinical Study in Drug-Resistant Tuberculosis

Fineline Cube Dec 26, 2024

China-based Clinical Research Organization (CRO) Boji Medical Technology Co., Ltd. (SHE: 300404) has announced receiving...

Company Drug

Jiangsu Hengrui Pharmaceuticals Secures NMPA Approvals for Prostate Cancer and Solid Tumor Clinical Trials

Fineline Cube Dec 26, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced receiving separate clinical trial approvals from...

Company Drug

Sichuan Biokin’s BL-M08D1 and CSPC’s SYS6010 Eye Breakthrough Therapy Designations in China

Fineline Cube Dec 26, 2024

The China’s Center for Drug Evaluation (CDE) website has indicated that China-based Sichuan Biokin Pharmaceutical...

Company Drug

CDE Indicates Priority Review for Boehringer Ingelheim’s Zongertinib and Peers

Fineline Cube Dec 26, 2024

The China’s Center for Drug Evaluation (CDE) website has indicated that several drugs, including German...

Company Drug

Zelgen Biopharmaceuticals’ ZG005 Gets NMPA Green Light for Solid Tumor and Lymphoma Clinical Trial

Fineline Cube Dec 26, 2024

Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) has announced receiving clinical approval from the National...

Company

Western Chongqing Southern Sichuan Precision Medicine Center Digital Platform Launches in Rongchang District

Fineline Cube Dec 26, 2024

On December 24, the Western Chongqing Southern Sichuan Precision Medicine Center Digital Information Platform was...

Company Drug

ProteLight Pharma’s Peceleganan (PL-5) Accepted for Review by China’s CDE

Fineline Cube Dec 26, 2024

China’s Center for Drug Evaluation (CDE) website has indicated that a market filing by local...

Company Deals

Innovent Biologics Partners with Suzhou ForLong to Explore Sintilimab and FL115 Combination in Solid Tumors

Fineline Cube Dec 26, 2024

China-based Innovent Biologics, Inc. (HKG: 1801) has announced a clinical study and supply agreement with...

Company Deals

Zhejiang Huahai Pharmaceutical’s Subsidiary Huaota Bio Secures $27.4 Million Investment

Fineline Cube Dec 26, 2024

Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521) has announced that its macromolecular drug-focused subsidiary, Shanghai...

Company Drug

Bristol-Myers Squibb’s Sotyktu Meets Primary Endpoints in POETYK PsA Studies

Fineline Cube Dec 25, 2024

US pharmaceutical major Bristol-Myers Squibb (BMS; NYSE: BMY) has announced positive results from the pivotal...

Company Deals

Bio-Thera Solutions Enters Licensing Agreement with Tabuk Pharmaceutical for BAT2206 in Saudi Arabia

Fineline Cube Dec 25, 2024

China-based Bio-Thera Solutions (SHA: 688177) has announced a licensing agreement with Tabuk Pharmaceutical Manufacturing Company,...

Company Deals

Achilles Therapeutics and AstraZeneca Seal $12 Billion Deal for TRACERx NSCLC Study Data

Fineline Cube Dec 25, 2024

UK-based Achilles Therapeutics plc has announced a landmark deal worth USD 12 billion with AstraZeneca...

Company Drug

Nuvation Bio’s Taletrectinib NDA for ROS1+ NSCLC Receives FDA Priority Review

Fineline Cube Dec 25, 2024

US-based Nuvation Bio Inc. (NYSE: NUVB) has announced that the New Drug Application (NDA) for...

Company Drug

Shanghai Henlius Biotech Initiates Patient Dosing in Global Phase III ELAINE-3 Study for Lasofoxifene

Fineline Cube Dec 25, 2024

Shanghai Henlius Biotech Inc., (HKG: 2696), a leading biopharmaceutical company based in China, has announced...

Company Medical Device

RaysightMed’s AngioQFA 100 Receives NMPA Approval for Coronary Artery Function Measurement

Fineline Cube Dec 25, 2024

China-based RaysightMed Co., Ltd has announced that it has received marketing approval from the National...

Company Deals

uBriGene Secures RMB 200 Million in Pre-Series D Financing to Expand ATMPs CDMO Services

Fineline Cube Dec 25, 2024

China-based uBriGene, a contract development and manufacturing organization (CDMO) focused on advanced therapy medicinal products...

Posts pagination

1 … 233 234 235 … 660

Recent updates

  • Senhwa Biosciences Launches Global Phase I/II Trial of First-in-Class Pidnarulex Combined with BeOne’s Tislelizumab in Solid Tumors Including Pancreatic Cancer
  • Amgen Announces $300M Additional Investment in US Manufacturing Network, Bringing Total Recent Commitments to Over $3 Billion
  • Pfizer Reports Q1 2026 Revenues of $14.5B with 7% Operational Growth Excluding COVID-19 Products, Reaffirms Full-Year Guidance
  • China’s NHC Establishes Regulatory Framework for Biomedical New Technologies with Interim Guiding Principles Effective May 1, 2026
  • UCB to Acquire Candid Therapeutics for $2.2B, Gaining Best-in-Class BCMA T-Cell Engager Cizutamig for Autoimmune Diseases
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Senhwa Biosciences Launches Global Phase I/II Trial of First-in-Class Pidnarulex Combined with BeOne’s Tislelizumab in Solid Tumors Including Pancreatic Cancer

Company

Amgen Announces $300M Additional Investment in US Manufacturing Network, Bringing Total Recent Commitments to Over $3 Billion

Company

Pfizer Reports Q1 2026 Revenues of $14.5B with 7% Operational Growth Excluding COVID-19 Products, Reaffirms Full-Year Guidance

Policy / Regulatory

China’s NHC Establishes Regulatory Framework for Biomedical New Technologies with Interim Guiding Principles Effective May 1, 2026

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.